

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: James A. RUSSELL, et al.

GROUP ART UNIT: Unassigned

SERIAL NUMBER: Unassigned

EXAMINER: Unassigned

10/549804

JC05 Rec'd PCT/PTO 19 SEP 2005

FILED: September 19, 2005

FOR: PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF PATIENT OUTCOME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The Applicant(s) wish to make of record the references listed on the attached PTO/ SB/08. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR § 1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending applications or issued patents which may be related to the present application. A copy of the patent(s) is attached along with PTO/ SB/08.
- ☐ A check is attached in the amount required under 37 CFR § 1.17(p).

CERTIFICATION

The undersigned certifies that

- ☐ each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.


PETITION

- ☐ Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR § 1.17(i)(1).

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account No. 50-0911. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
MCKENNA LONG & ALDRIDGE LLP


Shmuel Livnat
Registration No. 33,949

1900 K Street, N.W.
Washington, D.C. 20006
Telephone No: (202) 496-7500
Date: September 19, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	TBA
				Filing Date	September 19, 2005
				First Named Inventor	James A. RUSSELL, et al.
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	1	Attorney Docket Number	28903.0003

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US2002/0086838 A1	07-04-2002	Oh et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 98/53098	11-26-1998			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Raymond L. Benza, M.D., "Association of a Gene Polymorphism for PAI-1 with Primary Pulmonary Hypertension", Cardiopulmonary Critical Care Newsletter, Spring 2002, pages 7-9	
		Peter W. M. Hermans, et al., "4G/5G Promoter Polymorphism in the Plasminogen-Activator-Inhibitor-1 Gene and Outcome of Meningococcal Disease", Vol. 354, No. 9178, August 14, 1999, pages 556-560	
		D. R. Catchpoole, et al., "The Potential Tumour Suppressor Role for Caspase-9 (CASP9) in the Childhood Malignancy, Neuroblastoma", European Journal of Cancer, Pergamon Press, Oxford, GB, Vol. 37, No. 17, 2001, pages 2217-2221	
		E. Noguchi, et al., "Identification of Missense Mutation in the IL12B Gene: Lack of Association between IL12B Polymorphisms and Asthma and Allergic Rhinitis in the Japanese Population", Genes and Immunity, Nature Publishing Group, GB, Vol. 2, 2001, pages 401-403	
		Marie-Christine Gaillard, et al., "Identification of DNA Polymorphisms Associated with the V type Alpha-Antitrypsin Gene", Biochimica et Biophysica Acta, Gene Structure and Expression, Elsevier, Amsterdam, NL, Vol. 1444, No. 2, February 16, 1999, pages 166-170	
		Sally J. Dawson, et al., "The Two Allele Sequences of a Common Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Respond Differently to Interleukin-1 in HepG2 Cells", Journal of Biological Chemistry, Vol. 268, No. 15, 1993, pages 10739-10745	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--